APL-101 Oral Capsules

Drug identity checked against registry records

Also recorded as Bozitinib; CBI-3103; CBT-101; PLB-1001; Vebreltinib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224APLMPhase 2Recruiting2026-03-30Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.